Applied Nutrition PLC (GB:APN)
LSE:APN
Want to see GB:APN full AI Analyst Report?
Top Page
Applied Nutrition PLC
(LSE:APN)
Select Model
Select Model
Rating:78Outperform
Price Target:
322.00 p
▲(39.09% Upside)
Action:Reiterated
Date:06/04/26
The score is driven primarily by strong financial performance (rapid growth, solid profitability, low leverage, and strong free cash flow). Technicals are positive but tempered by overbought signals that elevate near-term risk. Valuation is moderately constraining due to a higher P/E and no available dividend yield.
Positive Factors
Conservative Balance Sheet
A very low debt burden relative to equity and materially expanded asset base provide durable financial flexibility. This conservative financing reduces solvency risk, supports investment capacity and resilience to shocks, enabling strategic reinvestment as the business scales.
Negative Factors
Modest Margin Softening
A recent modest decline in margins suggests emerging cost pressures or margin mix shifts as the company scales. If persistent, this could erode operating leverage, reduce free cash flow conversion and require margin-restoring actions such as pricing, cost control, or product mix changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
A very low debt burden relative to equity and materially expanded asset base provide durable financial flexibility. This conservative financing reduces solvency risk, supports investment capacity and resilience to shocks, enabling strategic reinvestment as the business scales.
Read all positive factors
Applied Nutrition PLC (APN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£727.50M
Dividend YieldN/A
Average Volume (3M)256.26K
Price to Earnings (P/E)27.0
Beta (1Y)0.71
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees270
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.11
Shares Outstanding250,000,000
10 Day Avg. Volume266,481
30 Day Avg. Volume256,256
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)6.03
Price to Sales (P/S)3.06
P/FCF Ratio21.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£330.00Price Target Upside42.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.12
Revenue Forecast (FY)£148.93M
Applied Nutrition PLC Business Overview & Revenue Model
Company Description
Applied Nutrition Plc, established in 2014 and based in Liverpool, United Kingdom, specializes in the international manufacture, wholesale, and retail of sports nutritional products. Its comprehensive product portfolio includes a diverse array of ...
How the Company Makes Money
null...
Applied Nutrition PLC Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 134.00M | 107.10M | 86.15M | 60.78M | 35.03M |
| Gross Profit | 60.40M | 48.20M | 40.38M | 26.51M | 13.61M |
| EBITDA | 38.90M | 29.70M | 25.38M | 18.61M | 10.42M |
| Net Income | 27.60M | 21.10M | 18.65M | 13.82M | 8.21M |
Balance Sheet | |||||
| Total Assets | 98.90M | 75.00M | 59.65M | 40.62M | 22.11M |
| Cash, Cash Equivalents and Short-Term Investments | 26.40M | 18.50M | 18.72M | 12.73M | 5.40M |
| Total Debt | 3.10M | 3.00M | 1.80M | 2.06M | 1.13M |
| Total Liabilities | 29.30M | 20.70M | 11.63M | 11.87M | 7.24M |
| Stockholders Equity | 69.60M | 54.30M | 48.02M | 28.75M | 14.87M |
Cash Flow | |||||
| Free Cash Flow | 16.30M | 15.20M | 6.28M | 7.62M | 6.20M |
| Operating Cash Flow | 17.20M | 16.20M | 7.32M | 8.59M | 6.49M |
| Investing Cash Flow | -900.00K | -1.00M | -407.00K | -989.00K | -267.00K |
| Financing Cash Flow | -800.00K | -15.10M | -339.00K | -217.00K | -8.98M |
Applied Nutrition PLC Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £727.50M | 27.04 | 44.55% | ― | ― | ― | |
75 Outperform | £2.90B | 18.76 | 14.99% | 2.06% | 9.52% | 17.22% | |
74 Outperform | £1.71B | 7.84 | 15.61% | 1.62% | 2.31% | 9.04% | |
69 Neutral | £1.55B | 161.43 | 0.73% | 0.79% | 25.76% | -73.03% | |
68 Neutral | £13.19B | 14.27 | 8.44% | 2.98% | -2.16% | -24.87% | |
65 Neutral | £2.45B | 25.38 | 6.17% | 5.27% | 15.55% | 42.40% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
GB:APN
Applied Nutrition PLC
291.00
166.00
132.80%
GB:ABF
Associated British Foods
1,885.00
-85.62
-4.34%
GB:CWK
Cranswick
5,420.00
214.63
4.12%
GB:PFD
Premier Foods
198.00
-0.68
-0.34%
GB:TATE
Tate & Lyle
553.50
54.73
10.97%
GB:GNC
Greencore
195.50
-28.62
-12.77%
Applied Nutrition PLC Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Applied Nutrition lifts outlook, buys U.S. plant and seals Mondelēz tie-up
Positive
Jun 1, 2026
Applied Nutrition plc has upgraded its guidance for the year to 31 July 2026, now forecasting revenue of about £148 million with EBITDA margins in line with market expectations, reflecting strong trading momentum. The company signalled that c...
Regulatory Filings and Compliance
Applied Nutrition Director Increases Stake with Share Purchase
Positive
Apr 13, 2026
Applied Nutrition plc disclosed that non-executive director and PDMR Marnie Millard purchased 13,257 ordinary shares in the company on 13 April 2026 at a price of £2.249112 per share. The director share purchase, reported under UK market abus...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Applied Nutrition posts 57% revenue surge and boosts capacity in strong first half
Positive
Mar 23, 2026
Applied Nutrition reported a strong first half to 31 January 2026, with revenue jumping 57% year-on-year to £74.5m, adjusted EBITDA up 56% to £21.5m and profit before tax up 54% to £20.9m, all ahead of management expectations. The g...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.